{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"ADC 1013"},{"type":"CodeName","name":"ADC-1013"},{"type":"CodeName","name":"JNJ-64457107"},{"type":"CodeName","name":"ADC1013"},{"type":"CodeName","name":"JNJ 7107"},{"type":"CASRegistryName","name":"2055640-86-1"}],"definition":{"html":"A human immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, mitazalimab binds to CD40 on antigen-presenting dendritic cells, which leads to the activation and proliferation of effector and memory T cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC). This eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system.","text":"A human immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, mitazalimab binds to CD40 on antigen-presenting dendritic cells, which leads to the activation and proliferation of effector and memory T cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC). This eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system."},"drugInfoSummaryLink":null,"nciConceptId":"C121538","nciConceptName":"Mitazalimab","termId":770043,"name":"mitazalimab","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"mitazalimab"}],"links":null}